Clinical Trials Browser

NCT04799275 2026-04-14

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2/3 Suspended

422 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04256317 2026-04-03

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Phase 2/3 Recruiting

316 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Phase 2/3 Not yet recruiting

216 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07425808 2026-02-23

FIT-AML

Phase 2/3 Not yet recruiting

230 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Phase 2/3 Recruiting

40 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2/3 Completed

76 enrolled 16 charts

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05939180 2024-04-09

VA vs DA for Newly Diagnosed Hig-risk AML

Phase 2/3 Recruiting

116 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05404906 2022-08-19

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Phase 2/3 Recruiting

124 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05175508 2022-01-03

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Phase 2/3 Unknown

180 enrolled

MyeloidOther hematologic neoplasm

Frailty, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 2/3 Completed

2,000 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute